Publisher： Adis International
ISSN： 1173-5503
Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.541, 2007-01, pp. : 6-6
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
Dasatinib tops imatinib for CML on economic level
Inpharma, Vol. 1, Iss. 1613, 2007-01 ,pp. :
Access to resources
Recommend
Dasatinib: a once-daily option for imatinib-resistant CML
Inpharma, Vol. 1, Iss. 1573, 2007-01 ,pp. :
Dasatinib a START-R in imatinib-resistant CML
Inpharma, Vol. 1, Iss. 1544, 2006-01 ,pp. :
Dasatinib off to a good start in imatinib-resistant CML
Inpharma, Vol. 1, Iss. 1523, 2006-01 ,pp. :
Nilotinib, dasatinib or imatinib in CML: no clear winner
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 656, 2012-01 ,pp. :